1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Atrion Corporation

Atrion Corporation

ATRI
Atrion CorporationUS flagNASDAQ Global Select
459.92
USD
+0.26
- -
809.44MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
58.3
59.06
65.67
71.89
78.95
78.67
79.41
82.27
83.59
80.39
90.96
102.69
96.15
103.16
Basic EPS, GAAP
12.9
11.72
13.22
14.2
15.67
15.12
19.82
18.49
19.82
17.49
18.22
19.59
11.02
7.13
Free Cash Flow per Basic Share
9.68
9.44
13.39
9.47
16.85
14.67
20.24
13.89
11.87
9.44
12.66
-2.77
-1.31
15.72
Dividend per Share
1.82
12.13
2.4
2.77
3.29
3.9
4.51
5.1
5.8
6.59
7.39
8.18
8.69
8.8
Book Value per Share
76.26
75.88
86.92
100.64
119.1
131.74
145.47
157.64
171.48
184.12
197.17
211.54
216.98
214.46
Tangible Book Value per Share
63.29
61.64
67.89
70.12
71.6
82.97
93.65
107.6
122.16
124.89
128.59
127.94
131.79
129.59
Basic Weighted Avg Shares
2
2
2
2
2
2
2
2
2
2
2
2
2
2
Sales/Revenue/Turnover
118
119
132
141
146
143
147
152
155
148
165
184
169
182
Operating Margin (%)
32.43
28.24
28.75
29
29.17
27.27
28.16
27.36
26.14
24.17
21.84
21.63
13.33
7.93
Depreciation Expense
7
8
9
9
9
9
9
9
11
12
13
14
15
16
Net Income, GAAP
26
24
27
28
29
28
37
34
37
32
33
35
19
13
Effective Tax Rate (%)
34.04
32.63
32.3
33.82
29.23
29.76
13.57
18.51
14.84
16.51
13.98
13.81
13.25
12.65
Profit Margin (%)
22.12
19.85
20.14
19.76
19.85
19.22
24.96
22.47
23.71
21.76
20.03
19.08
11.46
6.91
Working Capital
74
50
81
64
69
84
106
112
121
99
123
101
102
102
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
139
135
149
150
144
163
184
211
238
240
244
240
243
239
Return on Invested Capital (%)
19.67
16.5
18.03
18.02
20.44
17.86
20.48
17.14
15.35
12.43
12.78
14.13
8.12
5.18
Return on Capital (%)
18.23
15.4
16.22
14.96
13.88
11.99
14.38
12.22
12.05
9.79
9.5
9.52
5.14
3.32
Return on Common Equity (%)
18.23
15.4
16.22
14.96
13.88
11.99
14.38
12.22
12.05
9.79
9.5
9.52
5.11
3.31

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
660
812
796

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
115
113
119
Cash, Cash Equivalents & STI
6
10
18
Accounts Receivable, Net
23
25
27
Inventories
82
75
68
Total Current Liabilities
13
12
18
Payables & Accruals
13
12
18
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.23%
3%
1.4%
Free Cash Flow
-14.69%
-35.59%
-53.24%
Net Income, GAAP
-1.08%
-8.21%
-44.55%
Sales/Revenue/Turnover
2.7%
2.44%
-7.73%
Total Cash Common Dividend
12.3%
10.18%
4.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
47
49
45
43
184
2023
40
44
42
44
169
2024
47
49
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
4.72
5.21
4.95
4.7
19.59
2023
1.98
3.73
1.67
- -
11.02
2024
1.59
0.23
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1.95
1.94
2.15
2.14
8.18
2023
2.15
2.15
2.2
- -
8.69
2024
2.2
2.2
- -
- -
- -

Company Description

APIChat
CEO
David A. Battat
Full Time Employees
712
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
One Allentown Parkway Allen TX United States of America 75002-4211
IPO Date
Mar 18, 1980
CIK
0000701288
Website
atrioncorp.com
Similar Companies
Nephros, Inc. (NEPH)
Tarsons Products Limited (TARSONS.NS)
Nextgen Biomed Ltd (NXGN.TA)
Shanghai Kindly Enterprise Development Group Co.,LTD. (603987.SS)
Paramount Bed Holdings Co., Ltd. (PBHDF)
Regentis Biomaterials Ltd. (RGNT)
Business
Atrion Corporation, a developer and manufacturer of proprietary medical devices and components primarily for fluid delivery, cardiovascular, and ophthalmic applications, markets OEM components including valves, inflators, and manifolds to medical device manufacturers, pharmaceutical firms, and biotech companies; provides finished devices such as the Myocardial Protection System (MPS) for cardiac surgery, infusion therapy products, and ophthalmology instruments to hospitals, physicians, clinics, and treatment centers; and supplies high-pressure inflation devices, fluid delivery systems, cardiac surgery vacuum relief valves, Retract-O-Tape silicone vessel loops, Clean-Cut rotating aortic punch, and PerfectCut Aortotomy System for balloon catheter dilation, stent deployment, and heart bypass procedures. Founded in 1944 and headquartered in Allen, Texas, the company operates FDA-registered manufacturing facilities in Alabama, Florida, and Texas, serving niche healthcare markets globally with contract manufacturing services encompassing engineering design, prototyping, plastic injection molding, assembly, RF-welding, ultrasonic sealing, and sterile packaging. In August 2024, Nordson Corporation completed its acquisition of Atrion for approximately $800 million in an all-cash transaction valued at $460 per share, following a May 2024 merger agreement that expands Nordson's medical portfolio into infusion and cardiovascular therapies while integrating Atrion's three specialized facilities and product lines; prior to the acquisition, Atrion completed a factory expansion to enhance operational efficiency and support new product development targeting additional revenue streams by 2030.

Company News

APIChat

  • gurufocus.com

    Is Ares Management (ARES) a Value Opportunity After Q1 2026? GAAP EPS $0.46 (miss vs $1.39 est), Revenue not disclosed; GF Score 83/100, GF Value: 32.5% undervalued

  • prnewswire.com

    ATRI WELCOMES TWO INDUSTRY LEADERS TO ITS BOARD OF DIRECTORS

  • investorplace.com

    Smaller But Mighty: 3 Small-Cap Stocks for Long-Term Dividend Growth

  • zacks.com

    Atrion's (ATRI) Q2 Earnings Plummet Y/Y on Nordson Merger Costs

  • globenewswire.com

    Atrion Reports Second Quarter 2024 Results

  • prnewswire.com

    ATRI ALERT: The M&A Class Action Firm Investigates the Merger and August 19, 2024 Shareholder Vote of Atrion Corporation

  • accesswire.com

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

  • globenewswire.com

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, HTLF on Behalf of Shareholders

  • globenewswire.com

    URGENT UPDATE: The M&A Class Action Firm Investigates Merger and Imminent Vote on August 19, 2024, of Atrion Corporation – ATRI

  • prnewswire.com

    URGENT UPDATE: The M&A Class Action Firm Investigates Merger and Imminent Vote on August 19, 2024, of Atrion Corporation - ATRI

  • globenewswire.com

    SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Atrion Corporation – ATRI

  • prnewswire.com

    SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Atrion Corporation - ATRI

  • zacks.com

    Zacks Initiates Coverage of Atrion With Neutral Recommendation

  • prnewswire.com

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Atrion Corporation

  • prnewswire.com

    Shareholder Alert: Ademi LLP investigates whether Atrion Corporation has obtained a Fair Price for its Public Shareholders in its transaction with Nordson

  • businesswire.com

    ATRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Atrion Corporation Is Fair to Shareholders

  • globenewswire.com

    Atrion Corporation Enters Into Merger Agreement with Nordson Corporation

  • businesswire.com

    Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

  • globenewswire.com

    Atrion Corporation Declares Quarterly Cash Dividend

  • globenewswire.com

    Atrion Reports First Quarter 2024 Results